Studying COPD in African-Americans: Better late than never

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 1, 2008, Pages 1-3

  Dransfield, Mark T ^a,b   Bailey, William C ^a  

^a University of Alabama at Birmingham

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE;

AFRICAN AMERICAN; ASTHMA; CAUCASIAN; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DYSPNEA; EDITORIAL; HUMAN; MORTALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; SMOKING; SPIROMETRY; UNITED STATES;

AFRICAN AMERICANS; HUMANS; MORBIDITY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; UNITED STATES;

EID: 38949178052     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550701829339     Document Type: Editorial

References (21)

1. Criner GJ, Sharafkhaneh A, Player R, et al. Efficacy of tiotropium inhalation powder in African American patients with chronic obstructive pulmonary disease. J COPD 2007; this issue.
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002; 51:SS-6.
3. Chatila WM, Hoffman EA, Gaughan J, Robinswood GB, Criner GJ for the National Emphysema Treatment Trial Research Group. Advanced emphysema in African American and white patients: Do differences exist? Chest 2006; 130:108-118.
4. Chatila WM, Wynkoop WA, Vance G, Criner GJ. Smoking patterns in African Americans and whites with advanced COPD. Chest 2004; 125:15-21.
5. Dransfield MT, Davis JJ, Gerald LB, Bailey WC. Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Resp Med 2006; 100:1110-1116.
6. Ferdinand KC. Recommendations for the management of special populations: racial and ethnic populations. Am J Hypertens 2003; 16:50S-54S.
7. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344:1351-1357.
8. Carson P, Ziesche S, Johnson G, Cohn JN for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vaso-dilator-heart failure trials. J Card Fail 1999; 5:178-187.
9. Nelson HS, Weiss ST, Bleeker ER, Yancey SW, Dorinsky PM and the SMART Study Group. The salmeterol multicenter asthma research trial, a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 126:15-26.
10. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80.
11. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske Jr RF, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled, cross-over trial. Lancet 2004; 364:1505-1512.
12. Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL, Menjoge SS, Serby CW, Witek TJ. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224.
13. Federico MJ, Covar RA, Brown EE, et al. Racial differences in T-lymphocyte response to glucocorticoids. Chest 2005; 127:571-578.
14. Niewoehner R, Rice K, Cote C, Korducki L, Cassino C, Kesten S. Characteristics of COPD and response to once daily tiotropium in African Americans in the VA medical system. Proc American Thorac Soc 2005; 2:A543.
15. Johnson JA, Burlew BS, Siles RN. Racial differences in β-adrenoreceptor-mediated responsiveness. J Cardiovasc Pharmacol 1995 25:90-96.
16. Yoos HL, Kitzman H, McMullen A, et al. The language of breathlessness: do families and health care providers speak the same language when describing asthma symptoms?. J Pediatr Health Care 2005; 19:197-205.
17. Hardie GE, Gold WM, Janson S, et al. Understanding how asthmatics perceive symptom distress during a methacholine challenge. J Asthma 2002; 39:611-618.
18. Kifle Y, Seng V, Davenport PW. Magnitude estimation of inspiratory resistive loads in children with life-threatening asthma. Am J Respir Crit Care Med 1997; 156:1530-1535.
19. Hardie GE, Janson S, Gold WM, Carrieri-Kohlman V, Boushey HA. Ethnic differences: word descriptors used by African-American and white asthma patients during induced bronchoconstriction. Chest 2000; 117:935-943.
20. Dusser D, Bravo ML, Iacono P on behalf of the Mistral study group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27:547-555.
21. Dransfield MT, Bailey WC. COPD: racial disparities in susceptibility, treatment, and outcomes. Clin Chest Med 2006; 27(3):463-471.